The Motley Fool··Thomas NielViking Therapeutics' VK2735 Could Reshape Weight Loss Market—If Phase 3 Succeeds
Viking Therapeutics' VK2735 could threaten Novo Nordisk and Eli Lilly's GLP-1 dominance if phase 3 trials succeed, triggering potential threefold gains or severe losses.
PFELLYNVOVKTXclinical trialsVK2735